Published in PLoS One on November 23, 2011
MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. Oncotarget (2015) 1.05
HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS One (2012) 0.91
Toxoplasma histone acetylation remodelers as novel drug targets. Expert Rev Anti Infect Ther (2012) 0.88
HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population. Oncol Rep (2015) 0.85
PLGA-Loaded Gold-Nanoparticles Precipitated with Quercetin Downregulate HDAC-Akt Activities Controlling Proliferation and Activate p53-ROS Crosstalk to Induce Apoptosis in Hepatocarcinoma Cells. Mol Cells (2015) 0.83
By recruiting HDAC1, MORC2 suppresses p21 Waf1/Cip1 in gastric cancer. Oncotarget (2015) 0.81
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer. Oncotarget (2016) 0.79
LEPREL1 Expression in Human Hepatocellular Carcinoma and Its Suppressor Role on Cell Proliferation. Gastroenterol Res Pract (2013) 0.79
AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition. Oncotarget (2016) 0.79
Differential mRNA expression levels of human histone-modifying enzymes in normal karyotype B cell pediatric acute lymphoblastic leukemia. Int J Mol Sci (2013) 0.79
Molecular Signatures of Recurrent Hepatocellular Carcinoma Secondary to Hepatitis C Virus following Liver Transplantation. J Transplant (2013) 0.78
E2F1-mediated FOS induction in arsenic trioxide-induced cellular transformation: effects of global H3K9 hypoacetylation and promoter-specific hyperacetylation in vitro. Environ Health Perspect (2015) 0.77
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis. J Pharmacol Exp Ther (2013) 0.77
Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis. J Korean Med Sci (2015) 0.77
Epigenetic Alterations in Fanconi Anaemia: Role in Pathophysiology and Therapeutic Potential. PLoS One (2015) 0.76
The pentapeptide Gly-Thr-Gly-Lys-Thr confers sensitivity to anti-cancer drugs by inhibition of CAGE binding to GSK3β and decreasing the expression of cyclinD1. Oncotarget (2017) 0.75
Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP. Transl Oncol (2016) 0.75
A validated, transitional and translational porcine model of hepatocellular carcinoma. Oncotarget (2017) 0.75
Teng-Long-Bu-Zhong-Tang induces p21-dependent cell senescence in colorectal carcinoma LS174T cells via histone acetylation. J Exp Pharmacol (2017) 0.75
Clonogenic assay of cells in vitro. Nat Protoc (2006) 11.85
Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 9.12
Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (1998) 8.75
Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell (1997) 7.64
Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature (2000) 4.93
HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene (2007) 4.41
Histone deacetylases and cancer. Oncogene (2007) 4.30
HDAC family: What are the cancer relevant targets? Cancer Lett (2008) 4.17
Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene (1995) 3.96
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A (2004) 3.86
Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology (2001) 2.73
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer (2008) 2.67
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell (2004) 2.66
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res (2007) 2.60
Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun (1997) 2.22
BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci U S A (1999) 2.10
Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem (1997) 2.10
HDAC expression and clinical prognosis in human malignancies. Cancer Lett (2008) 1.99
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ (2005) 1.89
Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett (2009) 1.83
Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS (2005) 1.77
Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther (2006) 1.50
Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology (2005) 1.48
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology (2007) 1.21
Counting colonies of clonogenic assays by using densitometric software. Radiat Oncol (2007) 1.21
Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol (2005) 1.13
HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology (2006) 1.12
Histone deacetylase 3 represses p15(INK4b) and p21(WAF1/cip1) transcription by interacting with Sp1. Biochem Biophys Res Commun (2005) 0.99
HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity. Exp Cell Res (2008) 0.86
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene (2005) 4.07
Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res (2006) 1.98
Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS (2005) 1.77
Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res (2003) 1.73
Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res (2005) 1.70
Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J Virol (2006) 1.62
Critical enhancements of MRI contrast and hyperthermic effects by dopant-controlled magnetic nanoparticles. Angew Chem Int Ed Engl (2009) 1.57
Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology (2003) 1.56
Silicon nanotube battery anodes. Nano Lett (2009) 1.55
Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology (2013) 1.49
Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology (2005) 1.48
Totally laparoscopic total gastrectomy using endoscopic linear stapler: early experiences at one institute. J Laparoendosc Adv Surg Tech A (2012) 1.41
Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer (2006) 1.38
Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood (2002) 1.30
BRAF and KRAS mutations in stomach cancer. Oncogene (2003) 1.27
Genetic alterations of the KLF6 gene in gastric cancer. Oncogene (2005) 1.26
Nod1, a CARD protein, enhances pro-interleukin-1beta processing through the interaction with pro-caspase-1. Biochem Biophys Res Commun (2002) 1.23
ArrayCyGHt: a web application for analysis and visualization of array-CGH data. Bioinformatics (2005) 1.23
Altered expression of the KLF4 in colorectal cancers. Pathol Res Pract (2006) 1.23
CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res (2005) 1.20
Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch (2005) 1.20
ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Cancer Lett (2005) 1.19
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett (2013) 1.17
Decreased expression of tumour suppressor Bax-interacting factor-1 (Bif-1), a Bax activator, in gastric carcinomas. Pathology (2006) 1.16
Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int (2005) 1.11
Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer (2003) 1.11
Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas. Oncogene (2005) 1.09
Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer. APMIS (2003) 1.08
Surfactin from Bacillus subtilis displays anti-proliferative effect via apoptosis induction, cell cycle arrest and survival signaling suppression. FEBS Lett (2007) 1.07
Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem (2010) 1.07
Comparison of early outcomes of intracorporeal and extracorporeal gastroduodenostomy after laparoscopic distal gastrectomy for gastric cancer. J Laparoendosc Adv Surg Tech A (2011) 1.07
Loss of caspase-2, -6 and -7 expression in gastric cancers. APMIS (2004) 1.06
Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene (2005) 1.06
Somatic mutations of CASP3 gene in human cancers. Hum Genet (2004) 1.05
Overexpression of S100A4 is closely related to the aggressiveness of gastric cancer. APMIS (2003) 1.05
Inactivation of the Gastrokine 1 gene in gastric adenomas and carcinomas. J Pathol (2011) 1.04